CagriSema combines the GLP-1 agonist semaglutide in Novo Nordisk's blockbuster weight-loss drug Wegovy with dual amylin and calcitonin receptor agonist cagrilintide. The company is hoping that the ...
Novo Nordisk already has a fairly well-stocked pipeline of candidates, but one of its near-term hopes – CagriSema, which combines semaglutide with dual amylin and calcitonin receptor agonist ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback